Drug intelligence / Profile preview

REGEND-007

Development stage: Phase 1
Lead developer: Regend Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

**REGEND-007** is an investigational cell-based biologic being developed by Regend Therapeutics for **idiopathic pulmonary fibrosis**. Public descriptions identify it as a **generic airway basal layer stem cell preparation** administered by **intravenous infusion** in an early **Phase 1 exploratory, 3+3 dose-escalation study** designed to assess safety, tolerability, and preliminary efficacy over a 12-week follow-up period. The precise molecular target and detailed mechanism have not been publicly disclosed; based on the modality, it is best characterized as a **stem cell therapy intended to support airway or lung tissue repair/regeneration** rather than a target-defined pharmacology program.

Other names: Generic Airway Basal Layer Stem Cell Preparation

Beyond the preview

Go deeper on REGEND-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEND-007.

Explore the full profile